Pharmacology Quiz: Drug Interaction Types
20 questions · exam conditions
0:00
Drug Interaction TypesQuestion 1 of 20

Two analgesics, Drug X and Drug Y, are studied for their combined effect. The ED₅₀ for Drug X alone is 40 mg, and the ED₅₀ for Drug Y alone is 60 mg. When administered together, the same analgesic effect is achieved with a combination of 10 mg of Drug X and 30 mg of Drug Y. Which term best describes this interaction?

Additive
Synergistic
Antagonistic
Potentiation
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Drug Interaction Types

Practice Drug Interaction Types in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Drug Interaction Types, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

Two analgesics, Drug X and Drug Y, are studied for their combined effect. The ED₅₀ for Drug X alone is 40 mg, and the ED₅₀ for Drug Y alone is 60 mg. When administered together, the same analgesic effect is achieved with a combination of 10 mg of Drug X and 30 mg of Drug Y. Which term best describes this interaction?

  1. Additive
  2. Synergistic (correct answer)
  3. Antagonistic
  4. Potentiation
Explanation: The interaction is synergistic. For an additive effect, the sum of the fractions of the individual doses required to achieve the effect would equal 1. Here, 10 mg of Drug X represents 10/40 = 0.25 of its ED₅₀, and 30 mg of Drug Y represents 30/60 = 0.5 of its ED₅₀. The sum is 0.25 + 0.5 = 0.75. Since the desired effect is achieved when the sum of the dose fractions is less than 1, the drugs are working synergistically.

Question 2

Buprenorphine is a partial agonist at mu-opioid receptors, while morphine is a full agonist. If a patient physically dependent on high doses of morphine is administered buprenorphine, they can experience withdrawal symptoms. This phenomenon occurs because, in the presence of a full agonist, buprenorphine functions as a:

  1. Synergist
  2. Chemical antagonist
  3. Functional antagonist
  4. Competitive antagonist (correct answer)
Explanation: A partial agonist has both agonist and antagonist properties. When administered with a full agonist, a partial agonist competes for the same receptor. Because it has lower intrinsic activity, it displaces the full agonist, leading to a net decrease in receptor stimulation. This antagonistic effect can precipitate withdrawal in a dependent individual. It is a form of competitive antagonism because both drugs compete for the same binding site.

Question 3

In a preclinical cancer model, Drug X at its maximum tolerated dose causes a 15% reduction in tumor volume. Drug Y at its maximum tolerated dose causes a 20% reduction. When administered together at the same doses, the combination results in a 65% reduction in tumor volume. This interaction is best described as:

  1. Additive
  2. Synergistic (correct answer)
  3. Potentiation
  4. Antagonistic
Explanation: The combined effect (65% reduction) is substantially greater than the simple sum of the individual effects (15% + 20% = 35%). This is the definition of a synergistic effect. An additive effect would have resulted in approximately a 35% reduction. Potentiation is less accurate because both drugs have individual activity. An antagonistic effect would have resulted in a reduction of less than 35%.

Question 4

Which of the following drug combinations is based on a principle of additive rather than synergistic interaction for its therapeutic rationale?

  1. Trimethoprim and sulfamethoxazole for bacterial infections.
  2. Levodopa and carbidopa for Parkinson's disease.
  3. A beta-lactam antibiotic and a beta-lactamase inhibitor.
  4. Combining lorazepam and diazepam for management of anxiety. (correct answer)
Explanation: Lorazepam and diazepam are both benzodiazepines that act via the same mechanism at the GABA-A receptor. Combining two drugs from the same class with the same mechanism typically results in an additive effect. The other options are classic examples of synergy: (A) sequential blockade of folate synthesis, (B) potentiation via inhibition of peripheral metabolism, and (C) potentiation via inhibition of bacterial resistance enzymes.

Question 5

A patient on a stable dose of warfarin is prescribed sulfamethoxazole. Sulfamethoxazole is known to both displace warfarin from its binding sites on plasma albumin and inhibit its CYP2C9-mediated metabolism. Which of the following correctly predicts the net interaction and clinical consequence?

  1. An initial antagonistic effect followed by a long-term synergistic effect on anticoagulation.
  2. A net antagonistic effect, leading to a risk of thrombosis due to increased metabolism.
  3. A powerful synergistic effect, leading to a significantly increased INR and high risk of bleeding. (correct answer)
  4. An additive effect with a moderate, predictable increase in the INR.
Explanation: Both mechanisms increase the effect of warfarin. Displacing warfarin from albumin transiently increases the free, active drug concentration. Inhibiting its metabolism has a more sustained effect of increasing its half-life and concentration. The combination of these two effects is powerfully synergistic (potentiating), leading to a supratherapeutic INR and a significant increase in the risk of severe bleeding.

Question 6

A patient stabilized on warfarin experiences a subtherapeutic INR (indicating reduced anticoagulant effect) several weeks after starting treatment with carbamazepine. Carbamazepine is a potent inducer of the CYP450 enzymes that metabolize warfarin. In terms of the clinical anticoagulant effect, the interaction is best described as:

  1. Additive
  2. Synergistic
  3. Antagonistic (correct answer)
  4. Competitive
Explanation: The question asks to classify the interaction based on the clinical effect. Carbamazepine induces the enzymes that metabolize warfarin, leading to a lower plasma concentration and a reduced anticoagulant effect (subtherapeutic INR). This reduction in the therapeutic effect of warfarin is an antagonistic interaction from a clinical standpoint, even though the underlying mechanism is pharmacokinetic.

Question 7

A 68-year-old male with hypertension and heart failure is stable on lisinopril and furosemide. He begins taking ibuprofen for osteoarthritis. At a follow-up visit, his blood pressure is elevated and he has developed peripheral edema. The interaction of ibuprofen with his antihypertensive regimen is best described as:

  1. Synergistic
  2. Additive
  3. Antagonistic (correct answer)
  4. Pharmacokinetic induction
Explanation: The interaction is antagonistic. NSAIDs like ibuprofen inhibit prostaglandin synthesis. Prostaglandins are involved in maintaining renal blood flow and promoting sodium excretion. By inhibiting them, ibuprofen causes sodium and water retention and vasoconstriction, which counteracts the therapeutic effects of both the ACE inhibitor (lisinopril) and the diuretic (furosemide), leading to increased blood pressure and edema.

Question 8

A patient with myasthenia gravis is treated with pyridostigmine (an acetylcholinesterase inhibitor). The patient is subsequently prescribed oxybutynin for overactive bladder. Oxybutynin is a muscarinic receptor antagonist. What is the most likely outcome of adding oxybutynin to the patient's regimen?

  1. An improvement in both bladder symptoms and muscle strength.
  2. A synergistic effect leading to cholinergic crisis.
  3. Worsening of myasthenia gravis symptoms due to an antagonistic interaction. (correct answer)
  4. An additive effect on bladder control with no impact on muscle strength.
Explanation: Pyridostigmine increases acetylcholine levels to improve neuromuscular transmission in myasthenia gravis. Oxybutynin is an anticholinergic (muscarinic antagonist) that blocks the action of acetylcholine. This represents a functional antagonism. By blocking acetylcholine's effects, oxybutynin can counteract the therapeutic goal of pyridostigmine, potentially worsening the muscle weakness characteristic of myasthenia gravis.

Question 9

A patient stabilized on warfarin experiences a subtherapeutic INR (indicating reduced anticoagulant effect) several weeks after starting treatment with carbamazepine. Carbamazepine is a potent inducer of the CYP450 enzymes that metabolize warfarin. In terms of the clinical anticoagulant effect, the interaction is best described as:

  1. Additive
  2. Synergistic
  3. Antagonistic (correct answer)
  4. Competitive
Explanation: The question asks to classify the interaction based on the clinical effect. Carbamazepine induces the enzymes that metabolize warfarin, leading to a lower plasma concentration and a reduced anticoagulant effect (subtherapeutic INR). This reduction in the therapeutic effect of warfarin is an antagonistic interaction from a clinical standpoint, even though the underlying mechanism is pharmacokinetic.

Question 10

A patient with myasthenia gravis is treated with pyridostigmine (an acetylcholinesterase inhibitor). The patient is subsequently prescribed oxybutynin for overactive bladder. Oxybutynin is a muscarinic receptor antagonist. What is the most likely outcome of adding oxybutynin to the patient's regimen?

  1. An improvement in both bladder symptoms and muscle strength.
  2. A synergistic effect leading to cholinergic crisis.
  3. Worsening of myasthenia gravis symptoms due to an antagonistic interaction. (correct answer)
  4. An additive effect on bladder control with no impact on muscle strength.
Explanation: Pyridostigmine increases acetylcholine levels to improve neuromuscular transmission in myasthenia gravis. Oxybutynin is an anticholinergic (muscarinic antagonist) that blocks the action of acetylcholine. This represents a functional antagonism. By blocking acetylcholine's effects, oxybutynin can counteract the therapeutic goal of pyridostigmine, potentially worsening the muscle weakness characteristic of myasthenia gravis.

Question 11

A researcher observes that Drug P, an antagonist, shifts the dose-response curve of an agonist to the right. However, even at very high concentrations, Drug P does not reduce the maximum possible response to the agonist. A second antagonist, Drug Q, not only shifts the curve rightward but also depresses the maximum response. Which statement accurately classifies these antagonists?

  1. Drug P is a non-competitive antagonist; Drug Q is a competitive antagonist.
  2. Both Drug P and Drug Q are competitive antagonists.
  3. Drug P is a competitive antagonist; Drug Q is a non-competitive antagonist. (correct answer)
  4. Both Drug P and Drug Q are functional antagonists.
Explanation: A competitive antagonist binds reversibly to the same site as the agonist. Its effect can be overcome by increasing the agonist concentration, resulting in a rightward shift of the dose-response curve without a change in the maximal effect (Emax). This describes Drug P. A non-competitive antagonist binds to a different site or binds irreversibly, preventing the agonist from producing its maximal effect regardless of the agonist concentration. This reduces Emax and describes Drug Q.

Question 12

A patient receiving a heparin infusion develops severe bleeding. Protamine sulfate is administered, which is a strongly basic protein that binds to the acidic heparin molecule, forming a stable, inactive complex. This mechanism of reversing the anticoagulant effect is an example of:

  1. Chemical antagonism (correct answer)
  2. Competitive antagonism
  3. Physiological antagonism
  4. Non-competitive antagonism
Explanation: Chemical antagonism occurs when a drug reduces the concentration of an agonist by forming a chemical complex. Protamine sulfate (a base) directly binds to and neutralizes heparin (an acid), preventing it from interacting with its therapeutic target (antithrombin III). This is a direct chemical interaction, not a receptor-mediated event.

Question 13

Two analgesics, Drug X and Drug Y, are studied for their combined effect. The ED₅₀ for Drug X alone is 40 mg, and the ED₅₀ for Drug Y alone is 60 mg. When administered together, the same analgesic effect is achieved with a combination of 10 mg of Drug X and 30 mg of Drug Y. Which term best describes this interaction?

  1. Additive
  2. Synergistic (correct answer)
  3. Antagonistic
  4. Potentiation
Explanation: The interaction is synergistic. For an additive effect, the sum of the fractions of the individual doses required to achieve the effect would equal 1. Here, 10 mg of Drug X represents 10/40 = 0.25 of its ED₅₀, and 30 mg of Drug Y represents 30/60 = 0.5 of its ED₅₀. The sum is 0.25 + 0.5 = 0.75. Since the desired effect is achieved when the sum of the dose fractions is less than 1, the drugs are working synergistically.

Question 14

In a preclinical cancer model, Drug X at its maximum tolerated dose causes a 15% reduction in tumor volume. Drug Y at its maximum tolerated dose causes a 20% reduction. When administered together at the same doses, the combination results in a 65% reduction in tumor volume. This interaction is best described as:

  1. Additive
  2. Synergistic (correct answer)
  3. Potentiation
  4. Antagonistic
Explanation: The combined effect (65% reduction) is substantially greater than the simple sum of the individual effects (15% + 20% = 35%). This is the definition of a synergistic effect. An additive effect would have resulted in approximately a 35% reduction. Potentiation is less accurate because both drugs have individual activity. An antagonistic effect would have resulted in a reduction of less than 35%.

Question 15

A researcher observes that Drug P, an antagonist, shifts the dose-response curve of an agonist to the right. However, even at very high concentrations, Drug P does not reduce the maximum possible response to the agonist. A second antagonist, Drug Q, not only shifts the curve rightward but also depresses the maximum response. Which statement accurately classifies these antagonists?

  1. Drug P is a non-competitive antagonist; Drug Q is a competitive antagonist.
  2. Both Drug P and Drug Q are competitive antagonists.
  3. Drug P is a competitive antagonist; Drug Q is a non-competitive antagonist. (correct answer)
  4. Both Drug P and Drug Q are functional antagonists.
Explanation: A competitive antagonist binds reversibly to the same site as the agonist. Its effect can be overcome by increasing the agonist concentration, resulting in a rightward shift of the dose-response curve without a change in the maximal effect (Emax). This describes Drug P. A non-competitive antagonist binds to a different site or binds irreversibly, preventing the agonist from producing its maximal effect regardless of the agonist concentration. This reduces Emax and describes Drug Q.

Question 16

A patient receiving a heparin infusion develops severe bleeding. Protamine sulfate is administered, which is a strongly basic protein that binds to the acidic heparin molecule, forming a stable, inactive complex. This mechanism of reversing the anticoagulant effect is an example of:

  1. Chemical antagonism (correct answer)
  2. Competitive antagonism
  3. Physiological antagonism
  4. Non-competitive antagonism
Explanation: Chemical antagonism occurs when a drug reduces the concentration of an agonist by forming a chemical complex. Protamine sulfate (a base) directly binds to and neutralizes heparin (an acid), preventing it from interacting with its therapeutic target (antithrombin III). This is a direct chemical interaction, not a receptor-mediated event.

Question 17

Phenoxybenzamine binds covalently to alpha-adrenergic receptors, causing a long-lasting blockade. When an agonist like norepinephrine is administered afterward, its maximum effect is diminished. This interaction is best classified as:

  1. Competitive antagonism
  2. Non-competitive antagonism (correct answer)
  3. Functional antagonism
  4. Chemical antagonism
Explanation: Phenoxybenzamine's covalent (and thus irreversible) binding to the receptor effectively removes those receptors from the available pool. This prevents the agonist from achieving its maximal effect, even at very high concentrations. A reduction in the maximum effect (Emax) is the defining characteristic of non-competitive antagonism. Competitive antagonism (A) would not reduce the Emax.

Question 18

A patient on a stable dose of warfarin is prescribed sulfamethoxazole. Sulfamethoxazole is known to both displace warfarin from its binding sites on plasma albumin and inhibit its CYP2C9-mediated metabolism. Which of the following correctly predicts the net interaction and clinical consequence?

  1. An initial antagonistic effect followed by a long-term synergistic effect on anticoagulation.
  2. A net antagonistic effect, leading to a risk of thrombosis due to increased metabolism.
  3. A powerful synergistic effect, leading to a significantly increased INR and high risk of bleeding. (correct answer)
  4. An additive effect with a moderate, predictable increase in the INR.
Explanation: Both mechanisms increase the effect of warfarin. Displacing warfarin from albumin transiently increases the free, active drug concentration. Inhibiting its metabolism has a more sustained effect of increasing its half-life and concentration. The combination of these two effects is powerfully synergistic (potentiating), leading to a supratherapeutic INR and a significant increase in the risk of severe bleeding.

Question 19

A research study finds that combining Drug A and Drug B produces an effect significantly greater than the sum of their individual effects. A subsequent mechanistic study reveals that Drug A has no effect on the target receptor for Drug B, but it strongly inhibits the primary enzyme responsible for metabolizing Drug B. How should this drug interaction be classified based on its observed pharmacodynamic outcome?

  1. Pharmacokinetic potentiation
  2. Synergism (correct answer)
  3. Additive effect
  4. Competitive antagonism
Explanation: The question specifically asks for the classification of the observed pharmacodynamic outcome. The outcome is that the combined effect is greater than the sum of the individual effects. This is the definition of synergism. While the mechanism underlying this synergy is pharmacokinetic (inhibition of metabolism), the term that describes the final, observed effect on the body's response is synergism.

Question 20

To treat Parkinson's disease, Drug X, a dopamine precursor, is administered. However, it is largely metabolized in the periphery before reaching the brain. It is therefore co-administered with Drug Y, which inhibits the peripheral metabolizing enzyme but does not cross the blood-brain barrier and has no central effect on its own. This combination significantly increases the therapeutic benefit of Drug X. This is an example of a:

  1. Synergistic interaction (correct answer)
  2. Additive interaction
  3. Antagonistic interaction
  4. Competitive interaction at the dopamine receptor
Explanation: This describes the interaction between levodopa (Drug X) and carbidopa (Drug Y). Carbidopa has no therapeutic effect on its own but potentiates the action of levodopa by preventing its peripheral breakdown. This allows more levodopa to reach the brain. Potentiation is a type of synergistic interaction. It is not additive because Drug Y is inactive alone, and it is not antagonistic. The interaction does not occur at the dopamine receptor.